Medical device marketing runs into a constraint no other technical sector shares: what you may claim is bounded by what the device was cleared or approved to do. An agency that writes beautifully and does not understand intended use can create a promotional problem that reaches your regulatory affairs team long after the campaign ran. At the same time the commercial job is genuinely hard, because the buying committee usually includes a clinician who will use the device, a supply chain function that will price it, and a value analysis committee that will ask for evidence. This page describes those constraints, what separates specialist agencies from generalists, and the questions that reveal which you are talking to.
Intended use governs everything you publish
Device labeling and promotional material are regulated, and the governing idea is intended use: the claims that accompany the device define what it is for, and promotion beyond the cleared or approved indication is a regulatory problem rather than a marketing risk. The Food and Drug Administration publishes an overview of device regulation covering classification, clearance pathways and the general controls that apply, and the labeling requirements themselves sit in Title 21 of the Code of Federal Regulations, Part 801. Practically, that means every claim in a brochure, a landing page, a conference booth panel or a sales rep's deck must trace to the cleared indication and to evidence the company can produce. A competent agency treats regulatory review as a step in its own workflow, builds the review time into the schedule, and writes claims with the reviewer in mind rather than sending copy over and hoping.
The committee, not the clinician, is the buyer
For anything sold into a hospital, the clinician's enthusiasm is necessary and rarely sufficient. Value analysis committees ask what clinical evidence supports the switch, what it costs across a year including consumables and training, how it affects procedure time, and what happens to the products it replaces. That means the material that actually moves a sale looks less like advertising and more like documentation: evidence summaries, economic models, training and onboarding plans, integration and sterilization details, and reference sites willing to speak. Marketing for this sector is largely the work of making a champion's internal case easy to assemble. Where a device is sold to a private practice or a surgery center, the economics shift toward the owner operator and reimbursement questions become central, which is a different program even though the device is the same.
What drives the fee, and what you should insist on
Regulatory literacy is the premium. Writers who can work accurately inside cleared indications and who have sat through a promotional review cycle are scarce, and firms that employ them price accordingly. Beyond that, the fee tracks the number of audiences you need to reach, whether clinical and health economics content is included, and how heavy your internal review process is. Insist on a few things regardless of price. Copy must be traceable to sources you can produce on request. Reference or testimonial content involving patients requires proper authorization and cannot be gathered casually. Claims comparing your device to a competitor need substantiation before publication, not after a complaint. And your regulatory affairs team should meet the agency before the contract is signed, since their working relationship determines whether anything ships on time.
Vetting: the questions that separate specialists
Ask a candidate to explain intended use in their own words and watch whether the answer is confident or recited. Ask how they handle a marketing team that wants a claim regulatory will not approve, because that is the recurring conflict in this sector and experienced agencies have a method rather than an opinion. Ask which of their writers have worked on cleared device material and to see a piece, redacted if necessary. Ask how they build review cycles into a launch timeline and what buffer they use. Ask for a client reference at a comparable company size, since agencies used to large manufacturers with in house regulatory teams sometimes struggle at a startup where nobody owns that function. Firms with a track record in this field, including the broader medical marketing companies serving providers as well as manufacturers, will answer all of this without hesitation.
Questions people ask about medical device marketing agencies
Can we market a device before clearance?
Preannouncement of an uncleared device is tightly constrained and the rules differ by pathway and context, so this is a question for your regulatory counsel rather than your agency. What agencies can usefully build in the meantime is unbranded disease state education and the market groundwork that does not make product claims.
Do we need an agency with life science experience specifically?
For anything carrying product claims, yes. A generalist can competently handle brand identity, website engineering and paid media mechanics, but claim bearing copy needs someone who has worked inside promotional review. Mixed teams are common, with a specialist writing claims and a generalist handling the rest.
How long do review cycles add to a project?
Enough that it must be planned rather than absorbed. Ask your own regulatory team for their typical turnaround and build the schedule from that number, then require the agency to work to it. Launches slip far more often because review time was underestimated than because creative work ran late.
What can we do with clinician testimonials?
They are usable with care. Paid relationships create disclosure obligations and can trigger transparency reporting duties for the manufacturer, and the clinician's statements must stay within the cleared indication. Document the arrangement, keep the claims substantiated, and have both regulatory and legal review the final material.